SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Biogen, Eisai Present Five-Year Lecanemab Extension Data at CTAD

The data cover continuous lecanemab treatment in the five-year Clarity AD extension among patients with early Alzheimer's disease.

BIIB

Related stories